Cite
MLA Citation
Michael Boyer et al.. “Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer.” Clinical investigation, vol. 3, 2013, pp. 29–35. http://access.bl.uk/ark:/81055/vdc_100126063463.0x000015